Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients

Autor:	Cristina Maria Churruca, M. Beltran, Juan Cueva, M. E. Ortega-Izquierdo, Andrés Redondo, A. Arcusa Lanza, Antonio González-Martín, Isabel Bover, B. Ojeda, Ana Beatriz Sánchez-Heras, Elena García-Martínez, Beatriz Pardo, Ana Santaballa, A. Lopez-Rodriguez, Cristina Caballero, Pilar Lianes, A. Tibau, Jesús García-Donas, Antonio Casado, M. M. Gordon-Santiago
Rok vydání:	2011
Předmět:	Oncology Cancer Research medicine.medical_specialty Chemotherapy animal structures Bevacizumab business.industry medicine.medical_treatment medicine.disease Internal medicine medicine lipids (amino acids peptides and proteins) Epithelial ovarian cancer business Ovarian cancer medicine.drug
Zdroj:	Journal of Clinical Oncology. 29:e15590-e15590
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.e15590
Popis:	e15590 Background: To evaluate the safety and efficacy of bevacizumab (BEV) alone or combined with chemotherapy (CT) in a compassive use program sponsored by the Spanish Ovarian Cancer Research Gro...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::834bd630455dc230c8d07a2d139a1209 https://doi.org/10.1200/jco.2011.29.15_suppl.e15590 Zobrazit plný text záznamu